Picture of Pasithea Therapeutics logo

KTTA — Pasithea Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Pasithea Therapeutics jumps after $60 million public offering announcement

** Shares of clinical-stage biopharmaceutical company Pasithea Therapeutics KTTA.O rise almost 60% to $1.69

** KTTA is raising $60 million through a public offering of 80 million shares of its common stock at 75 cents per share compared to its previous close of $1.06

** Company says this funding will allow it to operate through at least H1 2028

** The public offering was led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors and Coastlands Capital

** KTTA is securing long-term funding to advance its ongoing research and clinical trials for PAS-004 for cancer treatment along with potential acquisitions or licensing deals

** Including session's moves, KTTA stock is down ~46.2% YTD

(Reporting by Anuj T in Bengaluru)

((anuj.t@thomsonreuters.com))

Recent news on Pasithea Therapeutics

See all news